HRT and Blood Clots: What Actually Raises the Risk

By the editorial team at The HRT Index — an independent comparison resource for HRT telehealth providers. Last verified: June 16, 2026. Medical sources reviewed: the FDA, DailyMed, the NHS, the National Blood Clot Alliance, ACOG, NICE, The Menopause Society, the CDC, and peer-reviewed studies. This page is free to read. If you use a provider link, we may earn a commission. It never changes the medical facts on this page or who we say a provider is right for.

HRT and blood clotsget talked about like one scary thing. They're not. The honest answer depends mostly on how you take estrogen — and that single detail is the difference between a real risk bump and almost none.

Here's the bottom line. Estrogen pills you swallow raise the risk of a blood clot. Estrogen you absorb through your skin — patches, gels, and sprays — generally does not. For most healthy women under 60, the overall risk stays low either way. But if you've already had a clot, or you have a clotting disorder, the rules change, and you should not start HRT online without a clinician.

HRT and Blood Clots: Your Risk by Type

We built this table by pulling the numbers from the actual studies and guidelines, then adding the single best question to ask your own clinician about each form. We score each route by three plain things: does it reach your whole body, does it pass through your liver first, and is the product FDA-approved or compounded. (“Systemic” means it reaches your whole body. “Local” means it mostly stays where you put it.)

Sources: ESTHER / Scarabin et al., via ACOG; Mohammed et al., J Clin Endocrinol Metab 2015; NHS; FDA on compounding.

Our take in one line:for a clot-worried reader, the first decision isn't “HRT or no HRT.” It's pill vs. skin vs. local — and then your personal history.

Does HRT cause blood clots?

HRT doesn't “cause” every blood clot, but estrogen can raise the chance of one in some people — and the form you take matters most. Pills carry more clot risk than patches, gels, or sprays. For many healthy women under 60, the actual risk stays low. Your personal history can change that.

Let's clear up the words first, because the fear lives in the words.

• VTEstands for venous thromboembolism. It's the umbrella term for a clot in a vein.
• A DVT (deep vein thrombosis) is a clot, usually in a leg. It can cause swelling, pain, or warmth.
• A PE (pulmonary embolism) is when a piece of clot breaks off and travels to the lungs. That one is an emergency.

These are veinclots. They're related to, but not the same as, the artery problems people also worry about with HRT, like stroke and heart attack. This page is about the vein clots — VTE.

So where does estrogen come in? Estrogen nudges up some of the proteins your blood uses to clot. Here's the key part. When you swallowestrogen, it goes through your liver before it reaches the rest of your body. That trip — clinicians call it “first-pass metabolism” — is what pushes those clotting proteins up. When estrogen goes in through your skin, it mostly skips that liver trip. So it barely moves those proteins at all.

That's the whole reason guidelines treat pills and patches differently. It's not marketing. It's plumbing.

Which type of HRT has the lowest blood clot risk?

For whole-body symptoms like hot flashes and night sweats, transdermal estrogen — a patch, gel, or spray — is generally the lowest-clot-risk way to take it, because it skips the liver. For vaginal or urinary symptoms only, low-dose vaginal estrogen is usually enough and is treated as low risk. Here's how each form stacks up.

Estrogen pills

Easy to take, often the cheapest, and they work. But they carry the most clot concern. In the ESTHER study, women on oral estrogen had about four times the clot odds of women not using hormones. Risk is highest in the first year and in people who already have risk factors.

The patch, gel, and spray (transdermal)

These deliver estradiol through your skin. In that same ESTHER study, women using skin estrogen had roughly the same clot risk as women using nothing at all. A meta-analysis comparing the two routes found pills carried clearly higher clot and DVT risk than skin estrogen. The NHS says patches, gels, and sprays don't raise clot risk the way tablets can. This is the form most menopause clinicians reach for first when clots are a concern.

Low-dose vaginal estrogen

This is for local symptoms — dryness, pain with sex, urinary irritation, repeat UTIs. The dose is tiny and very little reaches your blood, so the NHS says it doesn't raise clot risk. If hot flashes aren't your problem, you may not need whole-body estrogen at all. See our guide to vaginal estrogen.

Does the progesterone in HRT change your clot risk?

Yes — if you have a uterus and take systemic estrogen, you usually need a progesterone to protect your womb lining, and the type you use can nudge clot risk up or leave it flat. The natural form, micronized progesterone, looks clot-neutral in studies. An older synthetic one, MPA, looks worse.

Most people focus only on the estrogen and forget this part. But the progesterone (or “progestin” — a man-made version) matters too.

• Micronized progesterone (the body-identical kind, sold as Prometrium) appears clot-neutralin observational studies. (“Micronized” just means the particles are made small so the body absorbs them.)
• Dydrogesterone also looks favorable compared with other synthetics.
• Medroxyprogesterone acetate (MPA) — the synthetic used in the old, scary studies — is linked to higher clot risk than the others.

Real-world US data backs this up: women on estradiol plus micronized progesterone had significantly lower clot risk than women on the older conjugated estrogen plus MPA combination. So if you have a uterus and clots worry you, the progesterone is worth asking about by name. Sources: Maturitas 2023; Canonico et al. on progestogens and VTE.

Wait — didn't the FDA remove the HRT warnings in 2026?

In February 2026 the FDA removed the boxed warnings about cardiovascular disease, breast cancer, and dementia from the first menopausal hormone products. But clot risk did not vanish from the labels — those products still carry blood-clot warnings, and a past clot is still listed as a reason not to use systemic estrogen. The change reflects better evidence on benefits and timing. It does not mean estrogen stopped affecting your blood.

On February 12, 2026, the FDA approved label changes that removed the boxed-warning statements about cardiovascular disease, breast cancer, and probable dementia from the first six menopausal hormone products. The agency pointed to evidence that benefits often outweigh risks for women who start before age 60 or within 10 years of menopause.

Here's the part the headlines skip. Those products still address DVT and PE in their warnings, and active or past blood clots are still listed among the reasons not to use systemic estrogen. The boxed-warning language changed. The clot facts underneath it did not. The Menopause Society said the same thing: systemic estrogen still carries real risks for certain people that should be reviewed before starting.

So “FDA drops HRT warnings” is true — but it's about heart, breast, and brain risk in the right candidates. It is not a green light to ignore your clot history, your route, or your dose. Those still decide your clot risk. Read our full breakdown: FDA removes HRT warning — what it means.

How big is the blood clot risk from HRT, really?

For most healthy menopausal women, the absolute risk of a clot is low — even though estrogen can raise the relative risk. A “doubling” sounds frightening, but doubling a small number is still a small number for many people. What matters is your own starting risk before HRT.

This is where scary headlines do damage. “HRT doubles clot risk” is technically true for pills, and almost useless without context. Here's the context.

• For the average woman on menopausal hormone therapy, roughly 1 in 300 per year develops a clot. Estrogen raises the baseline two- to fourfold, but that baseline is small to begin with. Source: National Blood Clot Alliance.
• In the big WHI trial, combined oral therapy meant about 18 extra clots per 10,000 women per year. Source: WHI, via the FDA-approved label.
• Your background clot risk also climbs with age on its own — from under 1 per 1,000 women per year over age 50 to roughly 4 per 1,000 over age 80.
• The risk is highest in the first one to two years of pill use, and it returns to your normal baseline after you stop. Source: NICE.

Two takeaways. First, the route changes the math — pills add risk, skin estrogen mostly doesn't. Second, “average risk” may not be your risk.

And here's the reassuring flip side, said plainly: if you're a healthy woman under 60, within about 10 years of menopause, with no personal or family clot history, you are most likely a low-risk candidate — and the next section helps you confirm that, fast.

Who needs to be extra careful before starting HRT?

You need extra caution — and a real clinician, not a quick online form — if you have a past clot, a known clotting disorder, a stroke or heart attack history, unexplained vaginal bleeding, liver disease, a hormone-sensitive cancer, or any active clot symptoms. For everyone else, the main job is to match the right route to your symptoms.

To make this simple, we sort readers into three buckets. Find yours.

Things that raise your baseline clot risk, and belong on your list to mention: a prior DVT or PE, a known clotting disorder or Factor V Leiden, smoking, a BMI over 30, recent surgery, long periods of not moving (including long-haul flights), a strong family history of clots, and certain medical conditions. None of these is an automatic “no.” Most of them just push the answer toward a patch — and, in higher-risk cases, toward a specialist.

Can you take HRT if you've already had a blood clot or DVT?

If you've had a DVT or pulmonary embolism, don't treat online HRT like a quick checkout. Many systemic estrogen labels list a current or past clot as a reason not to use the product, so any decision should be made with a clinician who knows your full history. There may still be options — but they're chosen carefully, not by a form.

First, why the caution is real: the product labels say so. The FDA-approved labeling for systemic estrogen — including non-oral products like the patch — lists known or past venous clots (DVT and PE) among its warnings and reasons not to use it. Lower average risk from the skin route doesn't erase a product's contraindications. This isn't your online provider being difficult; it's the medication's own label.

When online HRT is not your first move: an active or recent clot, an unclear clot history, a known high-risk clotting disorder without specialist input, complex blood-thinner needs, or a stroke or heart attack history that needs hands-on management. In those cases, the trustworthy answer is to send you to a clinician who can evaluate you in full.

If hormones aren't your path right now, you're not out of options. See non-hormonal ways to manage menopause symptoms →

What blood clot warning signs need urgent care now?

Possible clot symptoms should never be handled through an HRT website or an intake form. New leg swelling or pain, sudden shortness of breath, chest pain, coughing blood, or fainting are urgent — get medical help right away. This matters most in the first months on HRT, when clot risk is highest.

What not to do:don't wait for your online provider to reply, don't fill out the quiz, and don't start, stop, or change HRT on your own if you think you might have a clot. Get checked first.

Are compounded “bioidentical” hormones safer for blood clots?

No — you shouldn't assume that. FDA-approved estradiol and progesterone can also be “bioidentical,” while compounded products are not FDA-approved and aren't checked by the FDA for safety, quality, or effectiveness before they're sold. The clot question still comes down to the route, the dose, and your history — not the word “bioidentical.”

“Bioidentical” means a hormone has the same structure as the one your body makes. It's a real thing — but it's become a marketing word. Here's what often gets lost:

• Bioidentical doesn't mean lower clot risk.A bioidentical estrogen as a pill still goes through your liver. As a patch, it doesn't. The route moves clot risk, not the label.
• FDA-approved options are bioidentical too. Estradiol patches, gels, and pills, and micronized progesterone capsules, are body-identical andFDA-approved — meaning they're made to consistent standards and checked for safety and effectiveness.
• Compounded is different. The FDA states that compounded drugs are not FDA-approved, and the FDA doesn't verify their safety, effectiveness, or quality before they're marketed. See our bioidentical vs. compounded HRT guide.

The National Academies — an independent group of top scientists — recommends limiting compounded hormone therapy to situations where a patient can'tuse an FDA-approved product, such as an allergy to an ingredient or a dose that isn't sold commercially.

So compounded hormones can be the right call in specific cases. They just shouldn't be sold to you as “safer for clots.” If a provider recommends one, ask: why isn't an FDA-approved option right for me? Exactly which hormones and doses are in it? Is it whole-body or local? What warnings apply?

Is the clot risk different for transgender (feminizing) hormone therapy?

This page is written for menopausal HRT. Feminizing hormone therapy uses different doses, monitoring, and goals, so clot questions there should be handled with a clinician experienced in gender-affirming care. The broad route lesson still shows up in the research, but the specifics — and the providers below — aren't built for it.

In pooled studies, clot rates in trans women on estrogen run around 2.3 per 1,000 person-years, which falls inside the range seen in cisgender women on hormone therapy, though the studies vary a lot. The biggest risk-raisers were the oldestrogen forms — ethinyl estradiol and diethylstilbestrol (DES) — which aren't used for this anymore, and transdermal estradiol is often preferred when clots are a concern. Care should be guided by a clinician who does gender-affirming hormone therapy.

What should you ask your doctor about HRT and blood clots?

The best appointment isn't one where you ask “Is HRT safe?” It's one where you ask “Given my clot history, my symptoms, and whether I have a uterus, should I use a pill, a patch, vaginal estrogen, a non-hormonal option, or specialist-guided care?” Specific questions get specific answers. Here's the script.

Print this. Take it in. You'll get more out of ten minutes than most people get in an hour.

1. “Am I asking about vein clots, stroke, heart disease — or all of them?”
2. “Do I have any risk factors that make whole-body HRT a bad idea for me?”
3. “If I need whole-body relief, is a transdermal patch a better choice for me than a pill?”
4. “If my symptoms are mainly vaginal or urinary, would low-dose vaginal estrogen be enough?”
5. “Do I have a uterus — and if so, which progesterone do you recommend, and why?”
6. “Should I be tested for a clotting disorder based on my history?”
7. “What should I do about HRT before surgery, or a long flight, or a long period of not moving?”
8. “Should I take aspirin or a blood thinner to offset the risk?” (Usually no — never start one on your own to “cancel out” HRT. Ask first.)
9. “What symptoms mean I should stop and get urgent care?”
10. “If HRT isn't right for me, what non-hormonal options should we try?”

And bring the basics: your age, your last period, your symptoms, whether you have a uterus, your personal and family clot history, whether you smoke, your rough BMI, any cancer history, and your current medications.

Where can you get HRT if blood clots are your main worry?

If clots are your main concern, choose a care path that can actually talk routes with you — FDA-approved patches, local vaginal estrogen, the right progesterone, and non-hormonal backups — and that reviews your history before prescribing. Don't pick a provider just because it's fast or cheap. Below is how the main telehealth options compare for this specific worry.

A quick, honest note: We're an independent comparison resource and we don't rank by who pays most. For a clot-worried reader, the providers that fit best are the ones that can offer FDA-approved transdermal or local options and take your history seriously.

Disclosure: the links below are affiliate links. We may earn a commission if you sign up. It doesn't change the facts in this table or who we recommend. Prices and policies checked June 16, 2026 — confirm current details at checkout.

For the specific worry on this page, two paths fit most cleanly: Midi, if you want clinician oversight plus insurance and FDA-approved options, and Winona's FDA-approved patch, if you want a cash-pay route to the lower-clot-risk form. If your symptoms are mainly local, ask any of them about vaginal estrogen instead.

How we made this guide

We built this page by keeping two things separate: the medical facts and the provider recommendations. Medical claims come from the FDA, DailyMed, the NHS, the CDC, ACOG, NICE, The Menopause Society, the National Blood Clot Alliance, and peer-reviewed studies. Provider claims come from the companies' own pages and were checked on June 16, 2026.

FAQ: HRT and blood clots